ORGO — Organogenesis Holdings Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1661181 ·
Last close
$1.38
Market Cap
$177.57M
52W High
$7.08
52W Low
$1.34
ADV30
644,387
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 42,805,000 | 19,132,000 | -52,180,000 | -96,267,000 | 406,446,000 | 46,097,000 | 118,314,000 |
| Mar 2026 | 36,250,000 | 10,478,000 | -68,891,000 | -53,156,000 | 519,992,000 | 91,379,000 | 138,645,000 |
| Dec 2025 | 225,071,000 | 175,153,000 | 65,229,000 | 43,700,000 | 598,730,000 | 93,679,000 | 164,812,000 |
| Sep 2025 | 150,487,000 | 114,236,000 | 21,649,000 | 21,567,000 | 509,827,000 | 63,745,000 | 123,848,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$31,973,000
Investing CF
$-11,133,000
Financing CF
$-47,731,000
CapEx
$-11,133,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.86
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-152,501,000
Inventory
$29,280,000
Receivables
$100,937,000
ST Investments
—
EBIT TTM
$-34,193,000
Pretax Income TTM
$-34,766,000
Interest Exp TTM
$-61,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$457,454,016
EBITDA
$-9,701,000
Free Cash Flow
$28,450,000
Enterprise Value
$352,442,080
Total Cash
$46,097,000
Total Debt
$66,950,000
Shares Out
128,674,548
Trailing EPS
$-0.79
Book Value
$1.15
ROE
-25.9%
ROA
-4.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 563,030,000 | 55,869,000 | 37,032,000 | 598,730,000 | 164,812,000 | 433,918,000 | -10,309,000 |
| Dec 2024 | 482,043,000 | 21,518,000 | 861,000 | 497,886,000 | 112,570,000 | 385,316,000 | 14,208,000 |
| Dec 2023 | 433,140,000 | 12,525,000 | 4,945,000 | 460,025,000 | 181,362,000 | 278,663,000 | 30,917,000 |
| Dec 2022 | 450,893,000 | 22,304,000 | 15,532,000 | 449,359,000 | 183,690,000 | 265,669,000 | 24,859,000 |
TTM Snapshot
Revenues TTM
$86,693,000
NetIncome TTM
$-18,843,000
OpCashFlow TTM
$0
Assets (Latest)
$598,730,000
Forward EPS
$-0.31
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.38 · call volume: 15 · put volume: 1
Expected Move to 2026-10-16:
±$0.45
(32.61%) —
implied range
$0.93 –
$1.83
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PEPG | PepGen Inc. | $179.15M | $2.59 | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $169.80M | $9.90 | — |
| MSLE | Satellos Bioscience Inc. | $186.92M | $8.81 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $187.56M | $3.71 | — |
| ANTX | AN2 Therapeutics, Inc. | $189.06M | $5.01 | — |
News headlines (Yahoo Finance, 1h cache)
Organogenesis (ORGO) Q2 2026 Earnings Call Transcript
2026-08-13 23:46 · Yahoo
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
2026-07-09 11:30 · Yahoo
Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update
2026-05-20 20:43 · Yahoo
Organogenesis (ORGO) Q1 2026 Earnings Transcript
2026-05-08 17:28 · Yahoo
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
2026-05-07 20:05 · Yahoo
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
2026-04-28 20:30 · Yahoo
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
2026-07-06 20:05 · Yahoo
Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution
2026-08-10 05:10 · Yahoo
Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary
2026-08-07 12:30 · Yahoo
Organogenesis Q2 Earnings Call Highlights
2026-08-07 07:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.